Non-motor complications in late stage Parkinson’s disease: recognition, management and unmet needs
Open Access
- 16 February 2021
- journal article
- other
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 21 (3) , 335-352
Abstract
Introduction: The burden of non-motor symptoms (NMS) is a major determinant of health-related quality of life in Parkinson’s disease (PD), particularly at its late stage. Areas covered: The late stage is usually defined as the period from unstable advanced to the palliative stage, characterized by a combination of emerging treatment-resistant axial motor symptoms (freezing of gait, postural instability, falls and dysphagia), as well as both non-dopaminergic and dopaminergic NMS: cognitive decline, neuropsychiatric symptoms, aspects of dysautonomia, pain and sleep disturbances (insomnia and excessive day-time sleepiness). Here, the authors summarize the current knowledge on NMS dominating the late stage of PD and propose a pragmatic and clinically focused approach for their recognition and treatment. Expert opinion: The NMS progression pattern is complex and remains under-researched. While dopamine-dependent NMS may improve with dopamine replacement therapy, non-dopamine dependent NMS worsen progressively and culminate at the late stages of PD. Furthermore, some PD specific features could interact negatively with other comorbidities, multiple medication use and frailty – the evaluation of these aspects is important in the creation of personalized management plans in the late stage of PD.Keywords
This publication has 160 references indexed in Scilit:
- Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?Journal of Neural Transmission, 2013
- Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety studyMovement Disorders, 2012
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelinesMovement Disorders, 2012
- Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: A prospective double‐blind trialMovement Disorders, 2011
- The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotensionMovement Disorders, 2011
- Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER)Movement Disorders, 2010
- Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placeboMovement Disorders, 2010
- Depression rating scales in Parkinson's disease: Critique and recommendationsMovement Disorders, 2007
- Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's diseaseMovement Disorders, 2007
- Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's diseaseMovement Disorders, 2003